Skip to Content

Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma

Download PQI pdf 0.15MB

Last Updated: April 29, 2024

By: Kelly Valla, PharmD, BCOP

About this PQI

The purpose of this PQI is to discuss the clinical considerations around the use of loncastuximab tesirine-lpyl (Zynlonta®) to optimize the outcomes for patients with relapsed/refractory large B-cell lymphoma.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI